alexa Hyaluronic Acid Mediated Enrichment of CD44 Expressing
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Hyaluronic Acid Mediated Enrichment of CD44 Expressing Glioblastoma Stem Cells in U251MG Xenograft Mouse Model

Arun Vaidyanath#, Hafizah Binti Mahmud#, Apriliana Cahya Khayrani, Aung KoKo Oo, Akimasa Seno, Mami Asakura, Tomonari Kasai* and Masaharu Seno

Department of Medical Bioengineering Science, Okayama University, Japan

#These authors have contributed equally to the article

Corresponding Author:
Tomonari Kasai
Laboratory of Nano-Biotechnology
Department of Medical Bioengineering Science
Faculty of Engineering, Graduate School of Natural Science and Biotechnology
Okayama University, 3.1.1 Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan
Tel: +81-86-251-8265
E-mail: [email protected]

Received Date: March 20, 2017; Accepted Date: April 03, 2017; Published Date: April 10, 2017

Citation: Vaidyanath A, Mahmud HB, Khayrani AC, Oo AKK, Seno A, et al. (2017) Hyaluronic Acid Mediated Enrichment of CD44 Expressing Glioblastoma Stem Cells in U251MG Xenograft Mouse Model. J Stem Cell Res Ther 7:384. doi:10.4172/2157-7633.1000384

Copyright: © 2017 Vaidyanath A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



Background: Glioblastoma is one of the most aggressive cancer with high mortality rates and poses several hurdles in the efficient chemotherapeutic intervention. Similar to other cancers, glioma also harbors CSCs, that are self-renewable, multipotent cells, which initiate the cancer incidence, chemotherapeutic resistance and cancer recurrence. The microenvironmental regulation in the brain tumor and metastasis involves the cooperative interaction between HA and CD44. CD44, being a multifaceted transmembrane glycoprotein by itself, or in combination with several other cell surface receptors, has been used as a marker for CSC isolation.

Methods: We established both adherent and nonadherent culture of U251MG cells by treating with high molecular weight HA. Further these cells were transplanted subcutaneously in Balb/c mouse for the generation of the xenograft model for the cancer stem cell. The tumor was further characterized for the establishment of the working model for molecular targeting studies of cancer stem cells.

Results: Here we showed the enrichment of the CD44 expressing population of glioblastoma cells by induction with hyaluronic acid. The non-adherent culture spheroids of U251MG cells showed up regulation in the CD44 expression along with aberrant activation of principal pluripotency genes OCT3/4, SOX2, KLF4 and Nanog. Using the HA-treated spheroid, we established an experimental xenograft mouse model with high angiogenesis enhanced tumor-initiating capacity while retaining the glioblastoma traits.

Conclusion: We characterized a mouse xenograft model of U251MG cells which could be a promising model system to study the molecular targeting approaches against CSCs in glioblastoma.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version